Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

MRNS has been the topic of a number of other research reports. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Royal Bank of Canada reduced their price objective on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Finally, TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Marinus Pharmaceuticals currently has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Trading Down 0.1 %

MRNS stock opened at $0.54 on Wednesday. The firm has a 50-day moving average price of $0.40 and a 200-day moving average price of $0.95. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $10.50. The stock has a market capitalization of $30.00 million, a P/E ratio of -0.22 and a beta of 1.03.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. abrdn plc raised its holdings in shares of Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after purchasing an additional 1,578,329 shares during the period. Suvretta Capital Management LLC raised its stake in Marinus Pharmaceuticals by 32.8% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after buying an additional 1,253,901 shares during the period. Franklin Resources Inc. boosted its holdings in Marinus Pharmaceuticals by 34.9% in the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after acquiring an additional 1,219,871 shares in the last quarter. GSA Capital Partners LLP grew its stake in Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after acquiring an additional 817,050 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at approximately $727,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.